awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34543009-4AB5E31F-C6A1-4753-8719-6F05FFAE1027
Q34543009-4AB5E31F-C6A1-4753-8719-6F05FFAE1027
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34543009-4AB5E31F-C6A1-4753-8719-6F05FFAE1027
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
P2860
Q34543009-4AB5E31F-C6A1-4753-8719-6F05FFAE1027
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34543009-4AB5E31F-C6A1-4753-8719-6F05FFAE1027
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
010cdee98237304e86bc74b1787cfdafdcc7dc9c
P2860
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.